K-Bio Technology Exports Surpass 21 Trillion Won, Setting Up Record Performance
Translated from Korean and summarized by DistantNews. Read the original for the full story.
At a glance
News
Named sources
Ongoing story
- South Korean pharmaceutical and biotechnology companies have signed 13 technology-export contracts since January, with disclosed deal values exceeding 21 trillion won.
- Drug-formulation and delivery platforms, as well as obesity and dementia drug candidates, are leading the exports.
- The performance has raised expectations for a record year after last year’s high.
South Korea’s pharmaceutical and biotechnology companies have already pushed technology exports beyond 21 trillion won this year, creating expectations for another record performance after last year’s result.
The deals are being driven by a range of technologies and drug candidates. Platforms that alter drug formulations and injection methods are among the products attracting overseas interest, alongside candidates for obesity and dementia treatments.
The Korea Pharmaceutical and Bio-Pharma Manufacturers Association said domestic companies had completed 13 technology-export contracts from January through the current period. The value of only the deals whose terms were disclosed has surpassed 21 trillion won.
The pace has strengthened hopes that South Korea’s bio industry will set a new annual record for technology exports for a second consecutive year.
About this summary
Originally published by Chosun Ilbo in Korean. Translated, summarized, and contextualized automatically by DistantNews, with a note on how the source frames the story. Not individually reviewed before publishing. How this works.
More Stories
From Our Blog
News in Translation: What Gets Lost, and How We Keep the Framing
Diaspora Media: How Communities Abroad Follow Home
Traveling Where the Press Is Not Free: How to Read the News There
The Digital Nomad's Guide to Local News
The Same Story, Different Countries: How Coverage Changes at the Border
